Comparison
While AOD-9604 is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials71111115, Tirzepatide is approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials24.
While AOD-9604 works as a synthetic fragment of human growth hormone corresponding to residues 176–191 with an added N-terminal tyrosine, retaining lipolytic but not growth-promoting actions; proposed to stimulate lipolysis and inhibit lipogenesis in adipose tissue, partly via β3-adrenergic pathways without significantly activating the full GH receptor–IGF-1 axis6171111, Tirzepatide is a 39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite24.
AOD-9604 is 16 amino acids long, whereas Tirzepatide is longer as it has a length of 39 amino acids. AOD-9604 is made up of a sequence of Tyrosine, Leucine, Arginine, Isoleucine, Valine, Glutamine, Cysteine, Arginine, Serine, Valine, Glutamic acid, Glycine, Serine, Cysteine, Glycine, Phenylalanine. Tirzepatide is made up of a sequence of sequence data not available in the current dataset.
AOD-9604
GH1
Tirzepatide
Not assigned in the current dataset.